Literature DB >> 17077950

Cushing's disease.

Martina De Martin1, Francesca Pecori Giraldi, Francesco Cavagnini.   

Abstract

Cushing's disease, i.e., pituitary ACTH-secreting adenoma causing excess glucocorticoid secretion, is a rare disease with significant mortality and morbidity. Timely diagnosis and appropriate treatment can alter the course of the disease and are therefore mandatory. First step of the diagnostic work-up is the endogenous glucocorticoid excess by measurement of urinary free cortisol, cortisol circadian rhythmicity or suppression by low doses of dexamethasone. In patients with equivocal results, second line tests, such as the dexamethasone-suppressed CRH test and desmopressin stimulation, usually enable the diagnosis to be confirmed. Measurement of plasma ACTH then allows the distinction between ACTH-dependent (e.g., pituitary or extrapituitary neuroendocrine tumors) and ACTH-independent causes (e.g., adrenal tumors). The last step in the diagnostic algorithm is often the most fraught with problems as the distinction between Cushing's disease and ectopic ACTH secretion relies on judicious interpretation of several diagnostic procedures. Positive responses to stimulation with CRH and inhibition by high doses of dexamethasone, if concurrent, enable a pituitary origin to be established whereas conflicting results call for inferior petrosal sinus sampling, the latter to be performed in experienced centres only. Visualisation of the tumor at pituitary imaging is helpful but not required for the diagnosis, as microadenomas often remain undectected by MRI and/or CT scan and, on the other hand, visualisation of a non-secreting incidentaloma may be misleading. Surgical removal of the pituitary tumor is the optimal treatment choice and should be attempted in every patient. Surgical failures as well as relapses can be treated by radiotherapy, medical therapy or, if necessary, bilateral adrenalectomy. Finally, patients cured of Cushing's disease require long-term monitoring given the risk of relapse and clinical burden of associated ailments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17077950     DOI: 10.1007/s11102-006-0407-6

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  87 in total

Review 1.  Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

Authors:  A Giustina; J D Veldhuis
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

2.  Assessment of cortisol and ACTH responses to the desmopressin test in patients with Cushing's syndrome and simple obesity.

Authors:  S Tsagarakis; V Vasiliou; P Kokkoris; G Stavropoulos; N Thalassinos
Journal:  Clin Endocrinol (Oxf)       Date:  1999-10       Impact factor: 3.478

Review 3.  The Cushing syndrome: an update on diagnostic tests.

Authors:  T B Kaye; L Crapo
Journal:  Ann Intern Med       Date:  1990-03-15       Impact factor: 25.391

4.  Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery.

Authors:  C Höybye; E Grenbäck; T Rähn; M Degerblad; M Thorén; A L Hulting
Journal:  Neurosurgery       Date:  2001-08       Impact factor: 4.654

5.  The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.

Authors:  J Estrada; M Boronat; M Mielgo; R Magallón; I Millan; S Díez; T Lucas; B Barceló
Journal:  N Engl J Med       Date:  1997-01-16       Impact factor: 91.245

6.  Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects.

Authors:  H M Schulte; G Benker; D Reinwein; W G Sippell; B Allolio
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

7.  Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years.

Authors:  G Minniti; D Traish; S Ashley; A Gonsalves; M Brada
Journal:  J Clin Endocrinol Metab       Date:  2004-11-23       Impact factor: 5.958

8.  Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.

Authors:  Luiz Augusto Casulari; Luciana A Naves; Paulo A Mello; Aldo Pereira Neto; Carla Papadia
Journal:  Horm Res       Date:  2004-11-19

9.  Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas.

Authors:  M Mitsumori; D C Shrieve; E Alexander; U B Kaiser; G E Richardson; P M Black; J S Loeffler
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-10-01       Impact factor: 7.038

10.  High prevalence of nodular thyroid disease in patients with Cushing's disease.

Authors:  C Invitti; R Manfrini; B M Romanini; F Cavagnini
Journal:  Clin Endocrinol (Oxf)       Date:  1995-09       Impact factor: 3.478

View more
  10 in total

Review 1.  Extrapituitary production of anterior pituitary hormones: an overview.

Authors:  S Harvey; C Arámburo; E J Sanders
Journal:  Endocrine       Date:  2011-11-15       Impact factor: 3.633

2.  Intraoperative multiple-staged resection and tumor tissue identification using frozen sections provide the best result for the accurate localization and complete resection of tumors in Cushing's disease.

Authors:  Jung Soo Lim; Seung Ku Lee; Se Hoon Kim; Eun Jig Lee; Sun Ho Kim
Journal:  Endocrine       Date:  2011-06-19       Impact factor: 3.633

3.  Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas.

Authors:  Jung Soo Lim; Mi-Kyung Lee; Eunhee Choi; Namki Hong; Soo Il Jee; Sun Ho Kim; Eun Jig Lee
Journal:  Endocrine       Date:  2018-11-24       Impact factor: 3.633

4.  Preanalytical stability of adrenocorticotropic hormone depends on both time to centrifugation and temperature.

Authors:  Zhi-Qi Wu; Hua-Guo Xu
Journal:  J Clin Lab Anal       Date:  2016-10-13       Impact factor: 2.352

5.  Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.

Authors:  R van der Pas; C de Bruin; A M Pereira; J A Romijn; R T Netea-Maier; A R Hermus; P M Zelissen; F H de Jong; A J van der Lely; W W de Herder; S M Webb; S W J Lamberts; L J Hofland; R A Feelders
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

6.  Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.

Authors:  C Erem; I Nuhoglu; M Yilmaz; M Kocak; A Demirel; O Ucuncu; H Onder Ersoz
Journal:  J Endocrinol Invest       Date:  2009-02       Impact factor: 4.256

7.  Associations among systemic blood pressure, microalbuminuria and albuminuria in dogs affected with pituitary- and adrenal-dependent hyperadrenocorticism.

Authors:  Yu-Hsin Lien; Tsai-Yuan Hsiang; Hui-Pi Huang
Journal:  Acta Vet Scand       Date:  2010-11-12       Impact factor: 1.695

8.  Thyrotoxicosis in a 13-year-old girl following pituitary adenectomy for Cushing's disease.

Authors:  Arndis Audur Sigmarsdottir; Ingvar Hakon Olafsson; Ólafur Kjartansson; Ragnar Bjarnason
Journal:  Clin Case Rep       Date:  2017-07-06

9.  ACTH-dependent Cushing's Syndrome: Diagnostic Pitfalls in Concomitant Non-secreting Pituitary Adenomas.

Authors:  Pietro Lucotti; Cesare Zoia; Elisabetta Lovati; Paolo Gaetani; Gino R Corazza
Journal:  Eur J Case Rep Intern Med       Date:  2016-03-30

10.  Effects of Oxytocin on Cell Proliferation in a Corticotroph Adenoma Cell Line.

Authors:  Jung Soo Lim; Young Woo Eom; Eun Soo Lee; Hyeong Ju Kwon; Ja Young Kwon; Junjeong Choi; Choon Hee Chung; Young Suk Jo; Eun Jig Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2019-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.